Adlai Nortye Ltd. American Depositary Shares Market Cap ($603.79 Million)
Market Cap & Net Worth: Adlai Nortye Ltd. American Depositary Shares (ANL)
Adlai Nortye Ltd. American Depositary Shares market cap. Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL) has a market capitalization of $603.79 Million ($603.79 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11010 globally and #2897 in its home market, demonstrating a -8.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adlai Nortye Ltd. American Depositary Shares's stock price $10.28 by its total outstanding shares 58734604 (58.73 Million).
Adlai Nortye Ltd. American Depositary Shares Market Cap History (2023–2026)
Adlai Nortye Ltd. American Depositary Shares market cap history from 2023 to 2026. Data shows change from $528.02 Million to $603.79 Million (-11.53% CAGR). Check Adlai Nortye Ltd. American Depositary Sh share price for real-time trading data and today's change.
Index Memberships
Adlai Nortye Ltd. American Depositary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #307 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #1133 of 3165 |
Weight: Adlai Nortye Ltd. American Depositary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adlai Nortye Ltd. American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adlai Nortye Ltd. American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see ANL operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
16.68x
Adlai Nortye Ltd. American Depositary Shares's market cap is 16.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $528.02 Million | $5.00 Million | -$109.23 Million | 105.70x | N/A |
| 2025 | $83.40 Million | $5.00 Million | -$35.53 Million | 16.68x | N/A |
Competitor Companies of ANL by Market Capitalization
Companies near Adlai Nortye Ltd. American Depositary Shares in the global market cap rankings as of October 31, 2026. See ANL net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Adlai Nortye Ltd. American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Adlai Nortye Ltd. American Depositary Shares (2023–2026)
Market capitalization of Adlai Nortye Ltd. American Depositary Shares from 2023 to today. Between 2023 and today, Adlai Nortye Ltd. American Depositary Shares's market cap moved from $528.02 Million to $ 603.79 Million, with a yearly change of -11.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $603.79 Million | +623.94% |
| 2025 | $83.40 Million | -47.12% |
| 2024 | $157.71 Million | -70.13% |
| 2023 | $528.02 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Adlai Nortye Ltd. American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $603.79 Million USD |
| MoneyControl | $603.79 Million USD |
| MarketWatch | $603.79 Million USD |
| marketcap.company | $603.79 Million USD |
| Reuters | $603.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more